Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them

Abstract

Compounds of formula (I): wherein X, Y, A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , T and R 5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

1 . A method of treating immune and auto-immune diseases in a subject in need thereof, comprising administration of an effective amount of a phosphate compound of formula (I): 
       
         
           
           
               
               
           
         
         wherein:
 X and Y represent a carbon atom or a nitrogen atom, wherein X and Y may not simultaneously represent two carbons atoms or two nitrogen atoms; 
 A 1  and A 2 , together with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring members which may have, in addition to the nitrogen represented by X or by Y, from one to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen, wherein the nitrogen atom may be substituted by a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group or a —C(O)—O-Alk group wherein Alk is a linear or branched (C 1 -C 6 )alkyl group, 
 or A 1  and A 2  independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )polyhaloalkyl, a linear or branched (C 1 -C 6 )alkyl group or a cycloalkyl; 
 T represents a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group optionally substituted by from one to three halogen atoms, a (C 1 -C 4 )alkyl-NR 1 R 2  group, or a (C 1 -C 4 )alkyl-OR 6  group; 
 R 1  and R 2  independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, 
 or R 1  and R 2  together with the nitrogen atom carrying them form a heterocycloalkyl; 
 R 3  represents a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl group, a (C 3 -C 10 )cycloalkyl-(C 1 -C 6 )alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, wherein one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated; 
 R 4  represents a phenyl substituted in the para position by a group of formula —OPO(OM)(OM′), —OPO(OM)(O − M 1   + ), —OPO(O − M 1   + )(O − M 2   + ), —OPO(O − )(O − )M 3   2+ , —OPO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —OPO(O − M 1   + )(O[CH 2 CH 2 O] n CH 3 ), or R 4  represents a pyrimidin-5-yl group substituted in the para position by a group of formula —OPO(O − M 1   + )(O − M 2   + ), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl or a heterocycloalkyl both composed of 5 or 6 ring members, while M 1   +  and M 2   +  independently of one another represent a pharmaceutically acceptable monovalent cation, and M 3   2+  represents a pharmaceutically acceptable divalent cation and n is an integer from 1 to 5, wherein the phenyl group may optionally be substituted by one or more halogen atoms; 
 R 5  represents a hydrogen atom, a halogen atom, a linear or branched (C 1 -C 6 )alkyl group, or a linear or branched (C 1 -C 6 )alkoxy group; 
 R 6  represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group; 
 R a , R b , R c  and R d , each independently of the others, represent, a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl, a linear or branched (C 2 -C 6 )alkenyl, a linear or branched (C 2 -C 6 )alkynyl, an aryl, a heteroaryl, a halogen atom, a linear or branched (C 1 -C 6 )alkoxy group, a hydroxy group, a linear or branched (C 1 -C 6 )polyhalo alkyl group, a trifluoromethoxy group, —NR 7 R 7 ′, nitro, R 7 —CO—(C 0 -C 6 )alkyl-, R 7 —CO—NH—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-O—, R 7 —SO 2 —NH—(C 0 -C 6 )alkyl-, R 7 —NH—CO—NH—(C 0 -C 6 )alkyl-, R 7 —O—CO—NH—(C 0 -C 6 )alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (R a ,R b ), (R b ,R c ) or (R c ,R d ) together with the carbon atoms carrying them form a ring composed of from 5 to 7 ring members, which ring may have from one to 2 hetero atoms selected from oxygen and sulphur, wherein one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched (C 1 -C 6 )alkyl; 
 R 7  and R 7 ′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl, a linear or branched (C 2 -C 6 )alkenyl, a linear or branched (C 2 -C 6 )alkynyl, an aryl or a heteroaryl, or R 7  and R 7 ′ together with nitrogen atom carrying them form a heterocycle composed of from 5 to 7 ring members, 
 
         it being understood that:
 “aryl” means a phenyl, naphthyl, biphenyl or indenyl group, 
 “heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens), 
 “cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, 
 “heterocycloalkyl” means any mono- or bi-cyclic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO 2  and nitrogen, 
 
         wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy may be optionally substituted by from 1 to 3 groups selected from optionally substituted, linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, linear or branched, optionally substituted (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —COOR′, —OCOR′, NR′R″, linear or branched (C 1 -C 6 )polyhaloalkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl, halogen, optionally substituted aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R′ and R″ independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group, 
         wherein the Het group defined in formula (I) may be optionally substituted by from one to three groups selected from linear or branched (C 1 -C 6 )alkyl, hydroxy, linear or branched (C 1 -C 6 )alkoxy, NR 1 ′R 1 ″ and halogen, wherein R 1 ′ and R 1 ″ independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group, 
         or an enantiomer, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base. 
       
     
     
         2 . The method according to  claim 1 , wherein R 4  represents phenyl substituted in the para position by a group of formula —OPO(OM)(OM′), —OPO(OM)(O − M 1   + ), —OPO(O − M 1   + )(O − M 2   + ), —OPO(O − )(O − )M 3   2+ , —OPO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —OPO(O − M 1   + )(O[CH 2 CH 2 O] n CH 3 ), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl or a heterocycloalkyl both composed of 5 or 6 ring members, and wherein M 1   +  and M 2   +  independently of one another represent a pharmaceutically acceptable monovalent cation, and M 3   2+  represents a pharmaceutically acceptable divalent cation and n is an integer from 1 to 5, wherein the phenyl group may optionally be substituted by one or more halogen atoms. 
     
     
         3 . The method according to  claim 1 , wherein R 4  represents phenyl substituted in the para position by a group of formula —OPO(O − Na + )(O − Na + ). 
     
     
         4 . The method according to  claim 1 , wherein X represents a carbon atom and Y represents a nitrogen atom. 
     
     
         5 . The method according to  claim 1 , wherein the group: 
       
         
           
           
               
               
           
         
         represents a 5,6,7,8-tetrahydroindolizine, an indolizine or a dimethylated pyrrole. 
       
     
     
         6 . The method according to  claim 1 , wherein T represents a methyl, (morpholin-4-yl)methyl or 3-(morpholin-4-yl)propyl group. 
     
     
         7 . The method according to  claim 1 , wherein R a  and R d  each represent a hydrogen atom and (R b ,R c ), together with the carbon atoms carrying them, form a 1,3-dioxolane group or a 1,4-dioxane group; or R a , R c  and R d  each represent a hydrogen atom and R b  represents a hydrogen atom or a halogen atom. 
     
     
         8 . The method according to  claim 1 , wherein R a  and R d  each represent a hydrogen atom, R b  represents a halogen atom and R c  represents a methoxy group. 
     
     
         9 . The method according to  claim 1 , wherein R a , R b  and R d  each represent a hydrogen atom and R c  represents a NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-O— group. 
     
     
         10 . The method according to  claim 1 , wherein R 3  represents a group selected from phenyl, 1H-indole, 1H-pyrrolo[2,3-b]pyridine, pyridine, 1H-pyrazole, 1H-pyrrole and 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine, those groups optionally having one or more substituents selected from linear or branched (C 1 -C 6 )alkyl, cyano and trideuteriomethyl. 
     
     
         11 . The method according to  claim 1 , wherein the compound of formula (I) is selected from:
 4-[{[3-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizin-1-yl]carbonyl}(phenyl)amino]phenyl disodium phosphate,   4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(pyridin-4-yl)amino]phenyl disodium phosphate,   4-({[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}[1-(trideuteriomethyl)-1H-pyrazol-4-yl]amino)phenyl disodium phosphate,   4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)amino]phenyl disodium phosphate,   4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(5-cyano-1-methyl-1H-pyrrol-3-yl)amino]phenyl disodium phosphate,   4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(1-methyl-1H-pyrazol-4-yl)amino]phenyl disodium phosphate,   4-[(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl){[5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}amino]phenyl disodium phosphate, and   4-[{[5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(1-methyl-1H-pyrazol-4-yl)amino]phenyl disodium phosphate,   
       or an enantiomer, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base. 
     
     
         12 . The method according to  claim 1 , wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.